First positive Phase III trial in acute ischemic stroke since 1996

Since 1996 when the tissue plasminogen activator (tPA) – Boehringer Ingelheim’s Actilyse - was approved, there have been nothing but failed attempts at developing a safe and effective treatment for ischemic stroke, according to Pharmazz.

Aiming to demonstrate this point, the privately-held US biopharma company today presented positive top-line results of its Phase III clinical trial evaluating sovateltide as a treatment for acute ischemic stroke.

Sovateltide demonstrated statistically-significant and clinically-meaningful improvements in multiple neurological outcomes in patients with acute cerebral ischemic stroke and was well tolerated, said Pharmazz, which presented these data in an oral session at the 14th World Stroke Congress in Singapore.